ALACHUA, Fla.--(BUSINESS WIRE)--RTI Surgical, Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, today announced the introduction of TETRAfuse® 3D Technology, providing surgeons a solution they have been seeking. From the beginning, surgeons have had to choose between bone in-growth, radiolucency or mechanical strength when selecting a spinal interbody implant. TETRAfuse 3D Technology is the first 3D printed polymer implant material that has demonstrated trabecular bone ingrowth while maintaining radiolucency and bone-like mechanical properties1.
“The 3D printing process creates a nano-rough surface on every aspect of the implant, not just the endplates,” noted Robert Watkins IV, M.D. of Marina Spine Center in Marina Del Ray, Calif. “This nano-rough surface facilitates bony ingrowth throughout the disc space from endplate to endplate, allowing deeper implant osseointegration.”
TETRAfuse 3D Technology was developed to offer surgeons an interbody material that participates in the fusion process while maintaining bone-like mechanical properties and radiolucent imaging. Bringing these features together combines the osseointegrative advantages of titanium and allograft bone with the benefits surgeons experience with PEEK. RTI will soon announce the release of a family of products manufactured with TETRAfuse 3D Technology, providing a platform that will have many derivative products.
“We are excited about the promise this cutting-edge technology holds for our surgeon customers and their patients,” said Camille Farhat, RTI chief executive officer. “Being the first to offer surgeons a 3D printed interbody polymer optimized to participate in fusion marks another significant milestone for RTI in our quest to continuously deliver relevant and innovative products without compromise.”
® indicates U.S. trademark registration. All trademarks and/or images are the property of their respective owners or holders.
1 Data on file at RTI Surgical, Inc. Animal and in vitro data may not be representative of clinical experience.
Clinical cases are unique and results may vary.
About RTI Surgical Inc.
RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.
Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov.
